XERS - CIK 0001867096
The table below shows Xeris Biopharma Holdings, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $28.63M | -$36.98M | -$47.02M | -$102.89M | -$95.53M | -$80.56M |
| Capital expenditure | - | - | - | - | $1.08M | $377.00K |
| Investing cash flow | -$696.00K | $4.88M | -$6.00M | $34.46M | $97.96M | -$27.41M |
| Dividends paid | - | - | - | - | - |
Xeris Biopharma Holdings, Inc. reported operating cash flow of $28.63M for fiscal year 2025. That is up 177.4% from -$36.98M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow grew from -$80.56M (FY 2020) to $28.63M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $11.39M | $36.17M | -$1.61M | $127.47M | $27.25M | $126.06M |